



News Release Dated August 9, 2019

MEDRx Co., Ltd.
Yonehiro Matsumura, CEO
Stock code: 4586, TSE Mothers

MEDRx and Daiichi Sankyo to discontinue a joint development program

MEDRx Co., Ltd. announces that MEDRx and Daiichi Sankyo Co., Ltd. (Head office: Chuo-ku, Tokyo; President: Sunao Manabe) have decided to discontinue a joint development program concerning a new product candidate using NCTS® (Nano-sized Colloid Transdermal System), which is an exclusive MEDRx transdermal technology.

MEDRx and Daiichi Sankyo have jointly conducted the development program for a product candidate with the goal of NDA approval in Japan. Since the result of the non-clinical study failed to demonstrate the expected result, MEDRx and Daiichi Sankyo have decided to discontinue this joint development.

Contact:
MEDRx Co., Ltd.
Management Department
E-mail: info@medrx.co.jp
